Trial Profile
A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Adegramotide/nelatimotide (Primary) ; Bevacizumab
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms WIZARD201G
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 08 Nov 2022 This study protocol amended as time frame for primary endpoint (Dose-limiting toxicity) changed from 4 weeks to Day 1 through Day 29.
- 08 Nov 2022 Status changed from active, no longer recruiting to completed.